Areva to begin US trial of cancer-fighting isotope

Jan 24, 2011

A subsidiary of the French nuclear giant Areva said Monday it had received US clearance to begin a clinical trial of an isotope that targets cancer cells.

"Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments," Areva Med said in a statement.

"This innovative approach, known as alpha radio-immunotherapy, specifically pinpoints and destroys while limiting to healthy cells."

The phase one trial, which assesses safety, will begin in 2011 and take about two years. The treatment's primary target will be pancreatic cancer, a company spokesman said.

"This landmark FDA authorization is a very important step that could lead to a potential treatment for very aggressive and lethal cancers," said Jacques Besnainou, CEO of Areva North America.

A spokeswoman declined to elaborate on the authorization, saying the agency does not comment on that are under way or about to begin.

Areva announced last year the construction of a facility to produce lead-212 in the Limousin region of France.

Explore further: Experimental brain tumour therapy considered for NHS fast track

add to favorites email to friend print save as pdf

Related Stories

UC to Test New Targeted Treatment for Prostate Cancer

Apr 14, 2010

(PhysOrg.com) -- The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second leading cause of cancer death in men. With a new partnership with Areva ...

FDA OKs vitamin C trial for cancer

Jan 12, 2007

Federal approval of a clinical trial on intravenous vitamin C as a cancer treatment lends credence to alternative cancer care, U.S. researchers said.

Scientists isolate cancer stem cells

Sep 11, 2008

After years of working toward this goal, scientists at the OU Cancer Institute have found a way to isolate cancer stem cells in tumors so they can target the cells and kill them, keeping cancer from returning.

Recommended for you

Chromosome buffers hold key to better melanoma understanding

16 hours ago

Buffers that guard against damage to the ends of chromosomes could hold the key to a better understanding of malignant melanoma – the deadliest form of skin cancer – according to new research from the University of Leeds.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Birger
not rated yet Jan 25, 2011
This article does not mention how the isotope is administred. So how does the treatment manage to target cancer cells and nothing else?
BTW it is not the lead isotope that attacks cancer, it is the alpha particle radiation that kills the cells.